|
||
| |||||||
|
Oltipraz, a candidate antiangiogenesis molecule Basic research efforts focusing on angiogenesis as a target for cancer therapeutics have yet to bear fruit. Of the 55 molecules in development, 43 are still at preclinical stages and considerable developmental activity is expected over the next decade. Oltipraz from Aventis is in clinical trials as an antischistosomal drug however it also appears to be an effective chemopreventative agent reducing the incidence of cancer. This is likely related to it's glutathione S transferase inducing activity. The anti-angiogenic properties of this molecule have now been investigated. Impressively Oltipraz reduced angiogenesis activity in vitro in human and rat assays. Furthermore in vivo, oral Oltipraz almost completely blocked the development of angiosarcoma xenografts. The observed efficacy of oltipraz in this model is comparable with that of SU 5416 and TNP-470, known antiangiogenic agents currently under clinical development. Oltipraz therefore represents an exciting anticancer candidate both through its well characterized chemopreventative activity and also through its more recently identified antiangiogenic activity. LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
| ||||||||
